Prostate Cancer Coverage from Every Angle

Niraparib Granted Breakthrough Therapy Designation in Metastatic Castration-Resistant Prostate Cancer

By: Sarah Jackson
Posted: Friday, October 11, 2019

On October 3, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to the orally administered PARP inhibitor niraparib for the treatment of patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who have received prior taxane chemotherapy and androgen receptor (AR)-targeted therapy.

The Breakthrough Therapy designation is based on data from the GALAHAD study ( identifier NCT02854436), a phase II, multicenter, open-label clinical trial evaluating the efficacy and safety of niraparib in the treatment of adult patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects who had received treatment with next-generation AR-targeting therapies and docetaxel. Data from the GALAHAD study were recently presented at the European Society for Medical Oncology (ESMO) 2019 Annual Congress (Abstract LBA50).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.